NCT02662764View on ClinicalTrials.gov

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 28, 2016

Primary Completion Date

April 14, 2017

Study Completion Date

May 5, 2017

Conditions
Moderate-to-severe Acute Pain
Interventions
DRUG

Zalviso™ 15 mcg

Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours

Trial Locations (11)

30333

Southeastern Center for Clinical Trials, Decatur

32960

G&G Research, Vero Beach

Orthopedic Center of Vero Beach, Vero Beach

33414

Visions Clinical Research, Wellington

34232

Gulfcoast Research Associates, Sarasota

35630

Eliza Coffee Memorial Hospital, Florence

35660

Shoals Medical Trials, Sheffield

77027

Westside Surgical Hospital, Houston

77089

Hermann Drive Surgical Hospital, Houston

84124

Jean Brown Research, Salt Lake City

85023

Arizona Research Center, Phoenix

All Listed Sponsors
lead

Talphera, Inc

INDUSTRY

NCT02662764 - Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg | Biotech Hunter | Biotech Hunter